ArticleNature microbiology2024
Commensal production of a broad-spectrum and short-lived antimicrobial peptide polyene eliminates nasal Staphylococcus aureus.
Article in Nature microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 45 citations in OpenAlex.
- Artificial intelligence catalyzes antimicrobial peptide design.Synthetic and systems biotechnology · 2027Review
- From sequence space to ecological function: microbiome-derived antimicrobial peptides as community effectors and therapeutic leads.Essays in biochemistry · 2026Review
- The Bacterial Landscape of Facial Skin: From Homeostasis to Skin Conditions.Dermatology and therapy · 2026Review
- Mass spectrometry-based metabolomics approaches to interrogate host-microbiome interactions in mammalian systems.Natural product reports · 2026Review
- Genetic modification of intractable bacterial clones by heat shock-facilitated phage transduction.Cell reports methods · 2026Article
- Antimicrobial Proteins from Limosilactobacillus fermentum GR-9 Inhibit Pathogens and Alleviate Salmonella Paratyphi B Infection in Mice.Probiotics and antimicrobial proteins · 2026Article
- Modular biosynthesis of microbiome-derived polyketides and nonribosomal peptides: insights and opportunities for Lactobacillaceae.Microbial cell factories · 2026Review
- Human and Marine Host Defense Peptides for Healthy Skin.Marine drugs · 2026Review
- SET-M33 peptide as a selectiveMicrobiology spectrum · 2026Article
- From Membrane Composition to Antimicrobial Strategies: Experimental and Computational Approaches to AMP Design and Selectivity.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Discovery of a Human Metabolite That Mimics the Bacterial Quorum-Sensing Autoinducer AI-2.Journal of the American Chemical Society · 2026Article
- A novel reverse lipase toxin substrate of themicroLife · 2026Article
- Dynamic remodeling of skin microbiota during healthy homeostatic and wound repair conditions.Frontiers in microbiology · 2026Review
- Integration of Postbiotics into Adult Diapers:Life (Basel, Switzerland) · 2025Article
- Distinct lung microbiota community states are associated with pulmonary nontuberculous mycobacterial disease prognosis.BMC microbiology · 2025Article
- Review
- Proteolytic-resistant self-assembling peptide nanofibers combat specific bacterial infections via trap and kill.Science advances · 2025Article
- Multicolumn Two-Dimensional Liquid Chromatography Screening Platform for Stereopeptidomics and Application to Antimicrobial Peptide Polyene and Lipopeptide.Analytical chemistry · 2025Article
- Complete genome sequence ofMicrobiology resource announcements · 2025Article
- Metabolic engineering approaches for the biosynthesis of antibiotics.Microbial cell factories · 2025Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
19 authors at 6 institutions in 4 countries.
Funding
Abstract
Antagonistic bacterial interactions often rely on antimicrobial bacteriocins, which attack only a narrow range of target bacteria. However, antimicrobials with broader activity may be advantageous. Here we identify an antimicrobial called epifadin, which is produced by nasal Staphylococcus epidermidis IVK83. It has an unprecedented architecture consisting of a non-ribosomally synthesized peptide, a polyketide component and a terminal modified amino acid moiety. Epifadin combines a wide antimicrobial target spectrum with a short life span of only a few hours. It is highly unstable under in vivo-like conditions, potentially as a means to limit collateral damage of bacterial mutualists. However, Staphylococcus aureus is eliminated by epifadin-producing S. epidermidis during co-cultivation in vitro and in vivo, indicating that epifadin-producing commensals could help prevent nasal S. aureus carriage. These insights into a microbiome-derived, previously unknown antimicrobial compound class suggest that limiting the half-life of an antimicrobial may help to balance its beneficial and detrimental activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.